Overview

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

Status:
Completed
Trial end date:
2019-04-24
Target enrollment:
Participant gender:
Summary
This Phase III study is designed to evaluate the efficacy and safety of KX2-391 Ointment in adult participants when applied to an area of skin containing 4-8 stable, clinically typical Actinic Keratosis (AK) lesions on the face or scalp.
Phase:
Phase 3
Details
Lead Sponsor:
Almirall, S.A.
Athenex, Inc.
Collaborator:
Athenex, Inc.
Treatments:
Tirbanibulin